MUMBAI, India, Sept. 22 -- Intellectual Property India has published a patent application (202611092063 A) filed by Ms. Rajandeep Kaur; Dr. Rupanshi Sahu; Ms. Palak Hindwal; Dr. Bharti Choudhary; Mr. Abhay Kumar Patel; Mr. Harshal Prajapati; Mr. Ved Prakash Dwivedi; Ms. Neha Gupta; Ms. Neera; and Mr. Himank Varshney on July 29, 2026, for A Biodegradable Nanoparticle-Based Pharmaceutical Composition For Controlled Delivery Of Anticancer Agents.
Inventors include Ms. Rajandeep Kaur; Dr. Rupanshi Sahu; Ms. Palak Hindwal; Dr. Bharti Choudhary; Mr. Abhay Kumar Patel; Mr. Harshal Prajapati; Mr. Ved Prakash Dwivedi; Ms. Neha Gupta; Ms. Neera; and Mr. Himank Varshney.
The application for the patent was published on September 18, 2026, under issue no. 38/2026.
Abstract: The present invention relates to a biodegradable nanoparticle-based pharmaceutical composition comprising chitosan-coated poly(lactic-co-glycolic acid) and polyethylene glycol-polycaprolactone hybrid nanoparticles co-encapsulating curcumin and paclitaxel for synergistic anticancer therapy. The hybrid nanoparticles exhibit mean diameters of 100-250 nanometers with encapsulation efficiencies exceeding 75 percent for both drugs. The chitosan coating provides pH-responsive release behavior with accelerated drug release at tumor acidic pH 5.0-5.5. The combination of curcumin-mediated NF-kB inhibition and P-glycoprotein efflux suppression with paclitaxel-induced microtubule stabilization achieves synergistic cytotoxicity with combination indices below 0.7 in MCF-7 and A549 cancer cell lines. In vivo studies demonstrate 83.1 percent tumor growth inhibition with reduced systemic toxicity. The formulation maintains excellent stability under accelerated storage conditions, providing a promising platform for controlled
Disclaimer: Curated by HT Syndication.
